ADVA
ADVA (FSE: ADV) today launched the industry’s first ePRC optical cesium atomic clock solution, protecting synchronization networks from costly and dangerous interruptions to satellite signals. The Oscilloquartz OSA 3350 ePRC+ provides unprecedented stability and significantly longer lifetime compared to all other ePRC cesium clocks. It’s also the first cesium clock on the market with built-in SNMP support. This innovation in the design of atomic clocks comes at a critical time when GNSS outages caused by jamming and spoofing attacks are on the rise. Long GNSS disruptions can cause severe network outages and so the OSA 3350 ePRC+ offers vital backup for mission-critical infrastructures that depend on satellite-based timing, such as mobile networks and power utilities. The OSA 3350 ePRC+ also meets the stringent performance demands as well as the cost points needed for mobile networks transitioning to 5G.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005036/en/
“Our OSA 3350 ePRC+ is a truly unique achievement and its importance to the industry can’t be overstated. It arrives at a crucial time with operators seeking an efficient way to deliver highly accurate, ultra-stable frequency and phase synchronization with significantly longer lifetime than existing cesium clocks. Now they can mitigate GNSS vulnerabilities by harnessing market-leading holdover performance for the most robust backup available,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Creating a viable commercial optical atomic clock has been a key mission for a long time. By achieving it, we’re making sure that communication service providers never again have to compromise between performance and lifetime. And, with a frequency stability that outperforms current ITU-T ePRC G.811.1 standards, our OSA 3350 ePRC+ provides the safety net needed for 5G networks.”
Featuring an all-digital design, the OSA 3350 ePRC+ leverages optical-pumping techniques. It greatly improves performance by providing an extremely stable frequency source. When used with enhanced primary reference time clocks (ePRTCs), the OSA 3350 ePRC+ delivers holdover for 14 days with an accumulated error of up to 35 nanoseconds. This far exceeds the ITU-T ePRC G.811.1 standard that requires an accumulated error under 70 nanoseconds. The OSA 3350 ePRC+ also delivers optimum stability for over 10 years, which is 100% longer than the lifespan of high-performance magnetic cesium clocks. With a fully modular design, the optical cesium solution features a wide range of telecom synchronization output interfaces and supports modern and secured management capabilities with SNMP. What’s more, the RoHS-compliant device is fully integrated into ADVA’s Ensemble management and control software suite for operational simplicity and ease of use.
“With our OSA 3350 ePRC+, we’re providing a critical component of tomorrow’s network synchronization. For decades, engineers have focused on maximizing the performance of magnetic cesium clocks despite their limitations. Now we’re opening up a new chapter in the history of time and frequency delivery with a technology that optimizes both performance and lifetime,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “The incredible stability and accuracy that our OSA 3350 ePRC+ generates will bring essential improvements needed for 5G and other critical infrastructures deriving timing from GNSS. At a time when jamming and spoofing attacks are increasing in frequency and duration, it offers vital backup to satellite-based timing. Our OSA 3350 ePRC+ is also fully integrated into our Ensemble network management software suite with built-in SNMP. It couldn’t be easier to monitor the health of the device and perform software upgrades remotely at the touch of the button.”
Watch this product video for more information: https://youtu.be/8jk4y6kH0Ug .
A supporting application video is available here: https://youtu.be/VarsNZNQB9w .
Further details can also be found in these slides: https://adva.li/osa-3350-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005036/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom